Compare Rent the Runway Inc (RENT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rent the Runway Inc vs Recursion Pharmaceuticals Inc — how do they compare? Rent the Runway Inc trades at $1.81 (market cap $61.75M), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 34.7× Rent the Runway Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RENT | RXRX | |
|---|---|---|
Market Cap | $61.75M | $2.14B |
Volume | 193,323 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $6.79 |
52-Week Low | $1.55 | $2.84 |
Typical Hold Time | 56 Days | 22 Days |
Enterprise Value | $228.75M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RENT trades at $1.68, up 1.82% today, amid a bearish technical signal and mixed fundamentals. The company reported Q2 2026 revenue growth of 20.8% YoY to $97.7M, with improved gross margins, but faces negative shareholder equity of -$182.5M and a high debt-to-asset ratio of 139.62. Recent CEO appointment and multiple law firm investigations create contrasting sentiment.
Outlook remains cautious due to persistent net losses, high leverage, and legal scrutiny, though revenue growth and margin expansion offer potential upside. Risks include execution challenges and debt burden, while analyst consensus leans Hold (57.89%) with no Sell ratings.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
